

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF THE S  
PUBLIC RECORD

02 AUG 21 PM 1

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>The Duberstein Group, Inc.</b>			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address <b>2100 Pennsylvania Ave, NW Ste 500</b> City <b>Washington</b> State/Zip (or Country) <b>DC 20037</b> <b>USA</b>			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name <b>John W. Angus, III</b>	Telephone <b>202-728-1100</b>	E-mail (optional)	5. Senate ID # <b>12675-253</b>
7. Client Name <input type="checkbox"/> Self <b>Pharmacia Corporation</b>			6. House ID # <b>31811024</b>

**TYPE OF REPORT** 8. Year 2002 Midyear (January 1-June 30)  **OR** Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  >> Termination Date \_\_\_\_\_

11. No Lobbyi

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input checked="" type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> &gt;&gt; \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>EXPENSES</b> relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> &gt;&gt; \$ _____ Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of</p> <p><input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(e) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature \_\_\_\_\_ Date 8/14/2002



Registrant Name: The Duberstein Group, Inc.Client Name: Pharmacia Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

**H.R.4954, Medicare Modernization and Prescription Drug Act of 2002, Medicare prescription drug benefit****S.1135, Medicare Reform Act of 2001, Medicare prescription drug benefit****S.358, Medicare Prescription Drug and Modernization Act of 2001, Medicare prescription drug benefit****EXECUTIVE BRANCH ACTIONS: Medicare prescription drug benefit**

17. House(s) of Congress and Federal agencies contacted

 Check if None**House of Representatives****The White House**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Angus, III, John W.</b>	
<b>Berman, Michael S.</b>	
<b>Champlin, Steven M.</b>	
<b>Duberstein, Kenneth M.</b>	
<b>Gandy, Henry M.</b>	
<b>Meyer, Daniel</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if None

Signature \_\_\_\_\_

Date 8/14/2002



Registrant Name: The Duberstein Group, Inc.

Client Name: Pharmacia Corporation

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues

**EXECUTIVE BRANCH ACTIONS: Food and Drug Administration nominations for Commissioner**

17. House(s) of Congress and Federal agencies contacted  Check if None  
**The White House**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Angus, III, John W.</b>	
<b>Berman, Michael S.</b>	
<b>Champlin, Steven M.</b>	
<b>Duberstein, Kenneth M.</b>	
<b>Gandy, Henry M.</b>	
<b>Meyer, Daniel</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date 8/14/2002

